| Description |
1 online resource (ix, 178 pages) : illustrations (some color) |
| Series |
Contributions to nephrology ; v. 147 |
|
Contributions to nephrology ; v. 147.
|
| Contents |
Purine metabolism and hyperuricemic states: 'The point of view of the rheumatologist' / G. Peronato -- Inherited hyperuricemic disorders / W.L. Nyhan -- Pharmacology of drugs for hyperuricemia: mechanisms, kinetics and interactions / F. Pea -- Hyperuricemic syndromes in cancer patients / A.-M. Tsimberidou, M.J. Keating -- Incidence and pathogenesis of tumor lysis syndrome / F. Locatelli, F. Rossi -- Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome / S. Jeha, C.-H. Pui -- Treatment and prevention of tumor lysis syndrome in children: experience of Associazione Italiana Ematologia Oncologia Pediatrica / A. Pession, E. Barbieri -- Intensive chemotherapy in patients with lymphoma: management of the risk of hyperuricemia / C. Tarella [and others] -- Hyperuricemia and bone marrow transplantation / G. Lambertenghi Deliliers, C. Annaloro |
|
Rasburicase therapy in acute hyperuricemia and renal dysfunction / C. Ronco [and others] -- Hyperuricemia in kidney transplantation / N. Perico [and others] -- Uric acid elimination in the urine: pathophysiological implications / M. Marangella -- Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients / G. Bellinghieri, D. Santoro, V. Savica -- Pharmacological treatment of acute renal failure in intensive care unit patients / D. Moreau |
| Summary |
Uric acid disorders are involved in both nephrological and hematological diseases. One of these crystal-associated diseases which has been known since antiquity is gout. More recently, tumor Lysis syndromes have been identified which affect patients with cancer, especially in the phase of cellular destruction after chemotherapy. The detection of these hyperuricemic syndromes, together with the improved understanding of urate handling by the kidney, have spurred new interest in the pathophysiology of hyperuricemic states, their clinical consequences and management. Moreover, the recent development of a recombinant form of urate oxidase transforming uric acid into allantoin (Rasburicase) has caused new interest in the pathophysiology of hyperuricemia and the potential applications of this new drug. The multidisciplinary approach of this book offers new insights into the metabolic syndromes in question by uniting authors from the fields of biochemistry, pharmacology, rheumatology, onco-hematology, and nephrology. The result is a compendium of the present knowledge in the field, which will also be very useful as a reference tool for professionals and students who want to expand their knowledge on this topic |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212 MiAaHDL |
|
English |
|
Current copyright fee: GBP36.40 24\0. Uk |
|
digitized 2010 HathiTrust Digital Library committed to preserve pda MiAaHDL |
|
Print version record |
| Subject |
Hyperuricemia.
|
|
Hyperuricemia -- physiopathology
|
|
Hyperuricemia -- therapy
|
|
Hyperuricemia
|
|
Hyperuricemia -- complications
|
|
Hyperuricemia
|
| Form |
Electronic book
|
| Author |
Ronco, C. (Claudio), 1951-
|
|
Rodeghiero, Francesco
|
| ISBN |
9783318011692 |
|
331801169X |
|
